These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26154815)

  • 61. Auditory false perceptions are mediated by psychosis risk factors.
    Barkus E; Smallman R; Royle N; Barkus C; Lewis S; Rushe T
    Cogn Neuropsychiatry; 2011; 16(4):289-302. PubMed ID: 21113827
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Using lexical analysis to identify emotional distress in psychometric schizotypy.
    Abplanalp SJ; Buck B; Gonzenbach V; Janela C; Lysaker PH; Minor KS
    Psychiatry Res; 2017 Sep; 255():412-417. PubMed ID: 28667929
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective.
    Hambrecht M; Häfner H
    Aust N Z J Psychiatry; 2000 Jun; 34(3):468-75. PubMed ID: 10881971
    [TBL] [Abstract][Full Text] [Related]  

  • 64. An investigation of a novel transdiagnostic model of delusions in a group with positive schizotypal symptoms.
    Cameron C; Kaplan RA; Rossell SL
    Cogn Neuropsychiatry; 2014; 19(4):285-304. PubMed ID: 24073661
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls.
    Korver N; Nieman DH; Becker HE; van de Fliert JR; Dingemans PH; de Haan L; Spiering M; Schmitz N; Linszen DH
    Aust N Z J Psychiatry; 2010 Mar; 44(3):230-6. PubMed ID: 20180725
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cannabis use and age at onset of schizophrenia.
    Veen ND; Selten JP; van der Tweel I; Feller WG; Hoek HW; Kahn RS
    Am J Psychiatry; 2004 Mar; 161(3):501-6. PubMed ID: 14992976
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Schizotypal Personality Questionnaire-Brief - Likert format: Factor structure analysis in general population in France].
    Ferchiou A; Todorov L; Lajnef M; Baudin G; Pignon B; Richard JR; Leboyer M; Szöke A; Schürhoff F
    Encephale; 2017 Dec; 43(6):558-563. PubMed ID: 27644915
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Self-esteem, coping, perceived social support and substance use in young adults with a cannabis dependence disorder].
    Dorard G; Bungener C; Corcos M; Berthoz S
    Encephale; 2014 Jun; 40(3):255-62. PubMed ID: 23928065
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Is there a common vulnerability in cannabis phenomenology and schizotypy? The role of the N170 ERP.
    Brooks GA; Brenner CA
    Schizophr Res; 2018 Jul; 197():444-450. PubMed ID: 29174334
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Lateralization of the 'negative priming' effect: relationships with schizotypy and with gender.
    Claridge GS; Clark KH; Beech AR
    Br J Psychol; 1992 Feb; 83 ( Pt 1)():13-23. PubMed ID: 1559143
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Psychosis-predictive value of self-reported schizotypy in a clinical high-risk sample.
    Flückiger R; Ruhrmann S; Debbané M; Michel C; Hubl D; Schimmelmann BG; Klosterkötter J; Schultze-Lutter F
    J Abnorm Psychol; 2016 Oct; 125(7):923-932. PubMed ID: 27583768
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The role of atypical semantic activation and stress in odd speech: implications for individuals with psychometrically defined schizotypy.
    Minor KS; Cohen AS
    J Psychiatr Res; 2012 Sep; 46(9):1231-6. PubMed ID: 22770671
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Psychopathology, social adjustment and personality correlates of schizotypy clusters in a large nonclinical sample.
    Barrantes-Vidal N; Lewandowski KE; Kwapil TR
    Schizophr Res; 2010 Sep; 122(1-3):219-25. PubMed ID: 20138738
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A latent profile analysis of schizotypal dimensions: Associations with psychopathology and personality.
    Fonseca-Pedrero E; Ortuño-Sierra J; de Álbeniz AP; Muñiz J; Cohen AS
    Psychiatry Res; 2017 Jul; 253():110-115. PubMed ID: 28364588
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prediction of psychopathology and functional impairment by positive and negative schizotypy in the Chapmans' ten-year longitudinal study.
    Kwapil TR; Gross GM; Silvia PJ; Barrantes-Vidal N
    J Abnorm Psychol; 2013 Aug; 122(3):807-15. PubMed ID: 24016018
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The normalities and abnormalities associated with speech in psychometrically-defined schizotypy.
    Cohen AS; Auster TL; McGovern JE; MacAulay RK
    Schizophr Res; 2014 Dec; 160(1-3):169-72. PubMed ID: 25449715
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Inferring about individual drug and schizotypy effects on cognitive functioning in polydrug using mephedrone users before and after clubbing.
    Herzig DA; Brooks R; Mohr C
    Hum Psychopharmacol; 2013 Mar; 28(2):168-82. PubMed ID: 23532749
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Additional support for the cognitive model of schizophrenia: evidence of elevated defeatist beliefs in schizotypy.
    Luther L; Salyers MP; Firmin RL; Marggraf MP; Davis B; Minor KS
    Compr Psychiatry; 2016 Jul; 68():40-7. PubMed ID: 27234181
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Metacognitive processes in psychometrically defined schizotypy.
    Chan CC; Spencer CC; West C; Viegas C; Bedwell JS
    Psychiatry Res; 2015 Dec; 230(2):279-86. PubMed ID: 26381182
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Reduced negative priming in schizotypy: failure to replicate.
    Moritz S; Andresen B
    Br J Clin Psychol; 2004 Jun; 43(Pt 2):211-215. PubMed ID: 15169619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.